Department of Chemistry and Center for Neuroscience Research, University at Albany, State University of New York, Albany, NY 12222, USA.
Biochemistry. 2010 Nov 2;49(43):9207-16. doi: 10.1021/bi100819v.
GluK2 is a kainate receptor subunit that is alternatively spliced at the C-terminus. Previous studies implicated GluK2 in autism. In particular, the methionine-to-isoleucine replacement at amino acid residue 867 (M867I) that can only occur in the longest isoform of the human GluK2 (hGluK2), as the disease (autism) mutation, is thought to cause gain-of-function. However, the kinetic properties of the wild-type hGluK2 and the functional consequence of this gain-of-function mutation at the molecular level are not well understood. To investigate whether the M867I mutation affects the channel properties of the human GluK2 kainate receptor, we have systematically characterized the rate and the equilibrium constants pertinent to channel opening and channel desensitization for this mutant and the wild-type hGluK2 receptor, along with the wild-type rat GluK2 kainate receptor (rGluK2) as the control. Our results show that the M867I mutation does not affect either the rate or the equilibrium constants of the channel opening but does slow down the channel desensitization rate by ~1.6-fold at saturating glutamate concentrations. It is possible that a consequence of this mutation on the desensitization rate is linked to facilitating the receptor trafficking and membrane expression, given the close proximity of M867 to the forward trafficking motif in the C-terminal sequence. By comparing the kinetic data of the wild-type human and rat GluK2 receptors, we also find that the human GluK2 has a ~3-fold smaller channel-opening rate constant but an identical channel-closing rate constant and thus a channel-opening probability of 0.85 vs 0.96 for rGluK2. Furthermore, the intrinsic equilibrium dissociation constant K(1) for hGluK2, like the EC(50) value, is ~2-fold lower than rGluK2. Our results therefore suggest that the human GluK2 is relatively a slowly activating channel but more sensitive to glutamate, as compared to the rat ortholog, despite the fact that the human and rat forms share 99% sequence homology.
GluK2 是一种代谢型谷氨酸受体亚基,其 C 末端存在可变剪接。先前的研究表明 GluK2 与自闭症有关。特别是,只有在人类 GluK2(hGluK2)的最长异构体中才能发生的氨基酸残基 867 处的蛋氨酸到异亮氨酸替换(M867I),作为疾病(自闭症)突变,被认为会导致功能获得。然而,野生型 hGluK2 的动力学特性以及这种功能获得突变在分子水平上的功能后果尚不清楚。为了研究 M867I 突变是否影响人类 GluK2 型谷氨酸受体的通道特性,我们系统地描述了该突变体和野生型 hGluK2 受体以及野生型大鼠 GluK2 型谷氨酸受体(rGluK2)的通道开放和通道脱敏的速率和平衡常数,作为对照。我们的结果表明,M867I 突变既不影响通道开放的速率,也不影响通道开放的平衡常数,但在饱和谷氨酸浓度下,通道脱敏速率减慢了约 1.6 倍。由于 M867 靠近 C 末端序列中的正向转运基序,这种突变对脱敏速率的影响可能与促进受体转运和膜表达有关。通过比较野生型人和大鼠 GluK2 受体的动力学数据,我们还发现,人类 GluK2 的通道开放速率常数小约 3 倍,但通道关闭速率常数相同,因此通道开放概率为 0.85,而 rGluK2 为 0.96。此外,hGluK2 的内在平衡解离常数 K1 与 EC50 值一样,比 rGluK2 低约 2 倍。因此,我们的结果表明,与大鼠同源物相比,人类 GluK2 是一种相对缓慢激活的通道,但对谷氨酸更敏感,尽管人类和大鼠形式共享 99%的序列同源性。